Although molecular mechanisms that determine the onset of a neuroendocrine tumour are complex and heterogeneous [124], a high prevalence of TP53 and retinoblastoma protein (Rb)1 mutations has been identified in SCLC genome-sequencing studies [125,126,127], suggesting their pivotal role in the development and progression of the disease. Here, TP53 is linked to small cell lung carcinoma.